Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neuroendocrine Tumors 11 Somatostatinoma 6 Insulinoma 4 Glucagonoma 4 Gastrinoma 4 Carcinoma, Neuroendocrine 4 Carcinoma, Islet Cell 3 Zollinger-Ellison Syndrome 2 Vipoma 2 Pheochromocytoma 2 Pancreatic Neoplasms 2 Carcinoma, Medullary 2 Carcinoid Tumor 2 Adenoma, Islet Cell 2 Pituitary Neoplasms 1 Non functioning pancreatic endocrine tumor 1 Neoplasms 1 Multiple Endocrine Neoplasia Type 2b 1 Multiple Endocrine Neoplasia Type 2a 1 Multiple Endocrine Neoplasia Type 1 1 Gastro-enteropancreatic neuroendocrine tumor 1 Gastro-entero-pancreatic Neuroendocrine Tumors 1 Carcinoma, Merkel Cell 1 Adrenal Cortex Neoplasms 1

Interventions

pasireotide 7 Cabergoline 7 Surgical Procedures, Operative 4 Temozolomide 3 Propofol 3 Hydrocortisone 3 Dexmedetomidine 3 lanreotide 2 Sevoflurane 2 Saline Solution 2 Rosiglitazone 2 Radiotherapy 2 Radiosurgery 2 Proton Therapy 2 Octreotide 2 Human Growth Hormone 2 Dexamethasone 2 Desflurane 2 Aminolevulinic Acid 2 pegvisomant 1 parecoxib 1 lutetium Lu 177 dotatate 1 loxoprofen 1 farletuzumab 1 entinostat 1 corticorelin ovine 1 antineoplaston AS 2-1 1 antineoplaston A10 1 Yoga 1 Visual Field Tests 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Pituitary Neoplasms × Capecitabine × Endocrine × Clear all

NCT03930771 2022-08-09

TMZ-Cap

Weill Medical College of Cornell University

Phase 2 Terminated

1 enrolled 8 charts

Pituitary Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡